Skip to main content
. 2022 Sep 23;53:101664. doi: 10.1016/j.eclinm.2022.101664

Figure 3.

Figure 3:

Haemotoxylin and eosin, and p53, staining of (a,b) post-treatment biopsies and (c,d) Cytosponge™ samples taken from a patient who received chemoradiotherapy for oesophageal adenocarcinoma. The biopsy stains show no atypia and wild-type p53 staining. The Cytosponge™ samples show atypia and p53 overexpression, indicating high risk of residual/recurrent tumour.